Cointime

Okairos

company

About

Okairos AG is a biopharmaceutical company focused on the discovery and development of genetic T-cell vaccines, including hepatitis C virus.

  • 1 - 10

Highlights

Total Funding Amount
$20.50M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Series B
Last Funding Money Raised
$20.50M
Industries
Biopharma,Biotechnology,Genetics,Health Care,Medical,Pharmaceutical
Founded date
Jan 1, 2007
Number Of Employee
1 - 10
Operating Status
Active

Okairos AG, a bio-pharmaceutical company, focuses on the discovery and development of genetic T-cell vaccines, including hepatitis C virus. The company also provides health and allied services. It has operations in Rome and Naples, Italy.

The company is based in Basel, Switzerland. Okairos AG was former subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$20.50M
Okairos has raised a total of $20.50M in funding over 2 rounds. Their latest funding was raised on Sep 14, 2010 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 14, 2010 Series B $20.50M 1 Versant Ventures — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Okairos is funded by 1 investors. Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Versant Ventures Yes Series B
Cointime
เนื้อหา
บริษัท